ClinicalTrials.gg
CompletedNCT01823289Updated May 31, 2013Results posted

An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections

A Phase 4 interventional study of Itraconazole in Pulmonary Fungal Infection, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-05-31.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of itraconazole sequential therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal infections ([IPFI]; lung diseases caused by fungal infection).

Read the detailed description

This is an open-label (all people know the identity of the intervention), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the efficacy and safety of itraconazole sequential therapy in participants with IPFI. The study duration will be 4 to 6 weeks. The treatment will be divided into the intravenous (into a vein) injection period and the oral solution administration (giving) period. During the intravenous injection period 200 milligram (mg) twice daily loading dose (large initial dose) will be given for first 2 days, 200 mg once daily for the subsequent 12 days. Then sequential itraconazole oral solution 200 mg twice daily will be given as maintenance therapy (treatment designed to help the original primary treatment to succeed) for 2-4 weeks. Participant's clinical, mycological and comprehensive efficacy will be assessed at Week 6. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Pulmonary Fungal Infection

Keywords

  • Invasive Pulmonary Fungal Infection
  • Itraconazole
03

In context

Lead sponsor

Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Probable or proven invasive pulmonary infectious participants (IPFI) - Hospitalized participants (at least hospitalized treatment and observation could be ensured during the intravenous injection period) - The participants (or legal representatives) have signed the forms.

Exclusion criteria

Exclusion Criteria:

  • Currently taking taboo drugs, such as terfenadine, astemizole, cisapride and HMG CoA reductase inhibitors (for example simvastatin, lovastatin, oral or intravenous midazolam or triazolam) - History of allergy or intolerance to imidazoles or pyrrole drugs (for example fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole) - Pregnant and breast feeding women, or women of child bearing age not taking effective measures - Participants with pure oral, urinary tract, and vaginal candidiasis (yeast infection) - Participants with fungal meningitis (inflammation of the meninges), active liver disease, renal insufficiency with the serum rate less than 30 milliliter per minute (ml/min), and current abnormal cardiac function such as congestive heart failure (condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body), or participants with history of congestive heart failure
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Itraconazole Sequential Therapy

    Drug: Itraconazole

Interventions

  • Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinical Efficacy

    Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.

    Time frame: Week 6

  2. Number of Participants With Mycological Efficacy

    Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.

    Time frame: Week 6

  3. Number of Participants With Comprehensive Efficacy

    Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.

    Time frame: Week 6

07

Results

Posted May 31, 2013

Participant flow

Participant flow — Overall Study
MilestoneItraconazole Sequential Therapy
Started71
Completed47
Not completed24
Withdrew: Lost to follow-up5
Withdrew: Adverse event5
Withdrew: Lack of efficacy1
Withdrew: Physician decision9
Withdrew: Administered contraindicated medicine1
Withdrew: Transaminase increased more than 3 times1
Withdrew: Drug affected efficacy and safety1
Withdrew: Creatinine clearance<30milliliter/minute1

Outcome measures

PrimaryNumber of Participants With Clinical Efficacy

Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.

Time frame:
Week 6
Reported as:
Number · participants
Number of Participants With Clinical Efficacy
participantsItraconazole Sequential Therapy
Cured8
Markedly Improved29
Improved18
Failed5
PrimaryNumber of Participants With Mycological Efficacy

Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.

Time frame:
Week 6
Reported as:
Number · participants
Number of Participants With Mycological Efficacy
participantsItraconazole Sequential Therapy
Fungi cleared20
Fungi not cleared10
PrimaryNumber of Participants With Comprehensive Efficacy

Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.

Time frame:
Week 6
Reported as:
Number · participants
Number of Participants With Comprehensive Efficacy
participantsItraconazole Sequential Therapy
Cured8
Markedly Improved32
Improved16
Failed4

Adverse events

Collected over From the signing of informed consent until end of the study (week 6).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Itraconazole Sequential Therapy—4/61 (6.6%)13/61 (21.3%)
Most frequent serious events
Most frequent serious events
EventItraconazole Sequential Therapy
DeathGeneral disorders2/61
EdemaGeneral disorders1/61
Fungal infectionImmune system disorders1/61
HemoptysisRespiratory, thoracic and mediastinal disorders1/61
Most frequent other events
Showing 10 of 22
Most frequent other events
EventItraconazole Sequential Therapy
HypokalaemiaMetabolism and nutrition disorders3/61
Hepatic function abnormalHepatobiliary disorders3/61
NauseaGastrointestinal disorders2/61
DiarrheaGastrointestinal disorders2/61
GranulocytopeniaBlood and lymphatic system disorders1/61
HyperbilirubinemiaHepatobiliary disorders1/61
GPT increasedHepatobiliary disorders1/61
Urinary tract infectionRenal and urinary disorders1/61
Renal function abnormalRenal and urinary disorders1/61
DermatosesSkin and subcutaneous tissue disorders1/61

Baseline characteristics

Age Continuous
Age Continuous(years)Itraconazole Sequential Therapy
Median55.5 (33.34 to 79.45)
Sex: Female, Male
Sex: Female, Male(Participants)Itraconazole Sequential Therapy
Female23
Male37
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2013
First posted
Apr 4, 2013
Start
Jun 2007
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Results first posted
May 31, 2013
Last update
May 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01823289
Responsible party
Sponsor
First posted
Apr 4, 2013
Start date
Jun 2007
Primary completion
Dec 2008
Completion
Jan 2009
Results posted
May 31, 2013
Last update
May 31, 2013

Study contacts

Xian-Janssen Pharmaceutical Ltd., China Clinical trial
study director · Xian-Janssen Pharmaceutical Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion